Coronary sinus Reducer (CSR) implantation is currently recommended to relieve angina in patients with refractory symptoms despite optimal medical therapy and maximally achievable revascularization. The impact of diabetes mellitus on outcome after CSR implantation is at present unknown. We aimed to explore the impact of CSR in refractory angina patients with diabetes mellitus. Data from consecutive patients undergoing CSR implantation at four different centres between 2014 and 2018 were included. Patients were divided according to the presence or absence of diabetes mellitus. Primary objective of this analysis was to evaluate the clinical response to CSR implantation defined as an improvement of ≥ 1 classes of the Canadian Cardiovascular Society (CCS) Classification. A total of 219 patients were included, 116 (53%) of whom had diabetes mellitus. The median age of the population was 69 years and 167 patients (76%) were male. There were no significant differences between groups of patients with and without diabetes mellitus with respect to CCS class at baseline (p value = 0.32) and at follow-up (p = 0.75). Over a median follow-up of 393 [224–1004] days, 84 (72%) of the patients with diabetes mellitus met the primary outcome, similarly to those without diabetes mellitus (p = 0.28). Fifty-three patients (24%) did not have an improvement in CCS class and no one experienced worsening of angina. CSR implantation was equally effective in improving angina symptoms among patients with refractory angina and diabetes mellitus compared to patients without diabetes mellitus.

尽管进行了最佳的药物治疗和最大程度的血运重建，但目前建议植入冠状窦减压器 (CSR) 以缓解顽固症状患者的心绞痛。目前尚不清楚糖尿病对 CSR 植入后结果的影响。我们旨在探讨 CSR 对糖尿病难治性心绞痛患者的影响。包括 2014 年至 2018 年间在四个不同中心接受 CSR 植入的连续患者的数据。根据有无糖尿病对患者进行分类。该分析的主要目的是评估对 CSR 植入的临床反应，该植入定义为加拿大心血管学会 (CCS) 分类中≥ 1 类的改善。共纳入 219 名患者，其中 116 名（53%）患有糖尿病。人群的中位年龄为 69 岁，167 名患者（76%）为男性。在基线时的 CCS 等级方面，有和没有糖尿病的患者组之间没有显着差异（p值 = 0.32）和随访时（p  = 0.75）。在 393 [224–1004] 天的中位随访中，84 名 (72%) 的糖尿病患者达到了主要结局，与没有糖尿病的患者相似 ( p  = 0.28)。53 名患者 (24%) 的 CCS 分级没有改善，没有人出现心绞痛恶化。与没有糖尿病的患者相比，CSR 植入在改善顽固性心绞痛合并糖尿病患者的心绞痛症状方面同样有效。